| 规格 | 目录价格 | 上海 | 安徽 | 武汉 | 成都 | 天津 | 深圳 | 会员价格 | 数量 |
|---|---|---|---|---|---|---|---|---|---|
| 5g | ￥ ǿōƂŷŷ | > 10 | -- | -- | -- | 1 | -- | ￥ ǿōƂŷŷ | - + |
| 10g | ￥ ŦüƂŷŷ | > 10 | -- | -- | -- | 2 | -- | ￥ ŦüƂŷŷ | - + |
| 25g | ￥ ƺōĊƂŷŷ | 5 | -- | -- | -- | 1 | -- | ￥ ƺōĊƂŷŷ | - + |
| 100g | ￥ ĒǿĩƂŷŷ | 1 | -- | -- | -- | -- | -- | ￥ ĒǿĩƂŷŷ | - + |
| 500g | ￥ ōƺĊōƂŷŷ | -- | -- | -- | -- | -- | -- | ￥ ōƺĊōƂŷŷ | - + |
| 1000g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
| 大货 | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
产品编号
1259443
CAS 号
154361-50-9
中文名称
卡培他宾（原料药）
MDL 号
MFCD00930626
分子量
359.35
存储条件
2-8°C
网页展示纯度为入库指导纯度值，各批次间存在一定差异，实际纯度以收货为准
熔点
沸点
闪点
旋光
描述
TPSA
122.91
LogP
0.7602
H_Acceptors
8
H_Donors
3
Rotatable_Bonds
6
[1]. Anne Polk, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013 Dec;39(8):974-84.
[2]. Chika Fujii, et al. [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine]. Gan To Kagaku Ryoho. 2013 Nov;40(12):2457-9.
[3]. Dan Rosmarin, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014 Apr 1;32(10):1031-9.
[4]. Hiroyuki Tanaka, et al. [Effect of capecitabine therapy on the blood levels of antiepileptic drugs - report of two cases]. Gan To Kagaku Ryoho. 2014 Apr;41(4):527-30.
[5]. Masatake Miyamoto, et al. [A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy]. Gan To Kagaku Ryoho. 2014 Apr;41(4):495-8.
警示图
警示词
Warning
危险申明
H341-H350-H360-H402
警告申明
P273-P280-P405-P501
GHS 编码
GHS08
1039388 现货
￥ ĊüƂŷŷ -5g
1168425 现货
￥ üĊƂŷŷ -5g
1215991 现货
￥ ƺǿĊĒƂŷŷ -100mg
1222770 现货
￥ ĒüƂŷŷ -5g
1259442 现货
￥ ĒŷüƂŷŷ -10mg
1284657 现货
￥ ǿĒĊƂŷŷ -25mg
1299721 货期咨询
1686714 货期咨询
1906563 货期咨询
1985689 货期咨询
现货供应
专业护航
售后无忧
品质保障
无需凑单
沪ICP备17019645号
400-821-0725
